be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and loratadine is a CYP3A4 substrate.
Loratadine; Pseudoephedrine: (Minor) Use caution if coadministration of ribociclib with loratadine is necessary, as the systemic exposure of loratadine may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and loratadine is a CYP3A4 substrate.
Lovastatin: (Moderate) Use caution if coadministration of ribociclib with lovastatin is necessary, as the systemic exposure of lovastatin may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and lovastatin is a CYP3A4 substrate.
Lovastatin; Niacin: (Moderate) Use caution if coadministration of ribociclib with lovastatin is necessary, as the systemic exposure of lovastatin may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and lovastatin is a CYP3A4 substrate.
Lumacaftor; Ivacaftor: (Major) Avoid coadministration of ribociclib with lumacaftor, as the systemic exposure of ribociclib may be decreased resulting in decreased efficacy; consider an alternative treatment with less potential to induce CYP3A. Ribociclib is extensively metabolized by CYP3A4 and lumacaftor is a strong CYP3A4 inducer; ivacaftor is a weak CYP3A4 inhibitor. (Major) If ribociclib and ivacaftor are taken together, administer ivacaftor at the usual recommended dose but reduce the frequency to once daily. Monitor for an increase in ivacaftor-related adverse reactions. Exposure to ribociclib may also increase, increasing in ribociclib-related adverse reactions (e.g., neutropenia, QT prolongation). Ribociclib is a moderate CYP3A4 inhibitor and ivacaftor is a CYP3A4 substrate. Ribociclib is also extensively metabolized by CYP3A4 and ivacaftor is a weak CYP3A4 inhibitor.
Lumacaftor; Ivacaftor: (Major) Avoid coadministration of ribociclib with lumacaftor, as the systemic exposure of ribociclib may be decreased resulting in decreased efficacy; consider an alternative treatment with less potential to induce CYP3A. Ribociclib is extensively metabolized by CYP3A4 and lumacaftor is a strong CYP3A4 inducer; ivacaftor is a weak CYP3A4 inhibitor.
Lurasidone: (Major) Decrease the dose of lurasidone if coadministration with ribociclib is necessary. The recommended starting dose of lurasidone for a patient already taking ribociclib is 20 mg per day (maximum, 80 mg per day). If the patient is already taking lurasidone when ribociclib therapy is started, reduce the lurasidone dose by one-half. The systemic exposure of lurasidone may be increased with concomitant use, resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and lurasidone is a CYP3A4 substrate in vitro.
Macitentan: (Moderate) Use caution if coadministration of ribociclib with macitentan is necessary, as the systemic exposure of macitentan may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and macitentan is a CYP3A4 substrate.
Maprotiline: (Major) Avoid coadministration of ribociclib with maprotiline due to an increased risk for QT prolongation and torsade de pointes (TdP). Systemic exposure of maprotiline may also be increased resulting in increase in treatment-related adverse |
